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Stabilisation of an amorphous form of ROY through a predicted 
co-former interaction 
Philip A. Corner,
a
 J. Jonathan Harburn,
a
 Jonathan W. Steed,
b
 James F. McCabe
c
 and David J. 
Berry*
a
The highly polymorphic compound ROY, notorious for the colour 
of its crystals, was the subject of an optimised high-throughput 
ultrasound-based co-crystal screen. This screen involved a 
computational pre-screen which highlighted an interaction 
between ROY and the potential co-former pyrogallol. We have 
shown that the presence of pyrogallol stabilises the amorphous 
form of ROY, highlighting the potential for future prediction of co-
amorphous behaviours.  
The olanzapine precursor ROY, 5-Methyl-2-[(2-
nitrophenyl)amino]-3-thiophenecarbonitrile, so called due to 
the red, orange and yellow crystal colours of its polymorphs, 
has been reported to exist in at least 10 polymorphic forms.
1
 
With seven of these forms structurally characterised, it was 
until recently
2
 the compound with the most polymorphs 
recorded in the Cambridge Structural Database (CSD).
3
 Due to 
the large number of polymorphic forms of ROY, it was chosen 
as a model compound for co-crystal screening. In this work 
ROY was first synthesised following the procedure reported in 
the patent for the synthesis of Olanzapine.
4
 Analysis of the 
resulting material is present in the supporting 
information†(S1-4). 
 
It is the practice of the pharmaceutical industry to perform 
comprehensive polymorph screening during the development 
of a drug.
5
 Although a metastable crystalline polymorphic form 
may give benefits in terms of solubility, the risk of conversion 
to the less bioavailable form at ambient conditions means this 
option is seldom used. Solubility advantage can also be 
conferred by the amorphous form.
6,7,8,9  
These phases however 
also have the potential to convert to a thermodynamically 
more stable crystalline form. The timescale of this conversion 
dictates the degree of opportunity or risk associated with the 
phase.
10
 Stabilisation techniques such as formulating the 
product with the addition of a polymer have been widely 
studied
11,12,13
 and can yield suitable stability at a cost – 
financial in terms of greater development needed for the 
formulation, additional regulatory requirements and issues 
surrounding the quantity of active pharmaceutical ingredient 
(API) that is contained within a formulation (i.e. drug 
loading).
14
 
Many of the polymers used in stabilising drugs in this way 
(such as PVP, PVPVA and HPMC
6
)
 
are hygroscopic
15
 and can 
lead to faster re-crystallisation of the drug through 
modification of the glass transition (Tg), removing the 
solubility benefit. There are also issues associated with HPMC 
which can cause a laxative effect.
16
 
These deficiencies have led to an expansion in research in co-
amorphous materials.
17,18
 co-amorphous phases have been the 
subject of significant study since 2009 as they have the 
potential to solve the problems of drug loading and toxicity. 
The co-amorphous approach has been defined as ‘the 
combination of two or more low molecular weight 
components that form a homogeneous amorphous single-
phase system’.
19
 The stabilising interactions have been seen to 
occur via a number of mechanisms including hydrogen 
bonding, π- π stacking and salt formation. There are currently 
no purported means of predicting which small molecules will 
create such interactions and stabilise APIs in the desired 
fashion. This means many thousands of potential molecules 
could be used as the second entity, therefore some 
mechanism for practical selection would be beneficial.   
Co-crystal formation can also convey advantageous properties 
to pharmaceuticals.
20,21
 Without extensive screening it is not 
currently possible to know with certainty which co-formers, if 
any, will form a co-crystal with a given API. Crystal structure 
prediction (CSP) is a developing field with the potential to 
correctly predict structure improving year on year, as 
evidenced by the blind tests organised by the Cambridge 
Crystallographic Data Centre (CCDC).
22
 There is still much work 
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to be done regarding prediction of the result of introducing a 
co-former into the crystal structure, in terms of physical and 
chemical properties. It is therefore necessary to perform 
empirical screening and analysis to obtain co-crystals for a 
given API and determine their properties. With the predictive 
advances in mind it is prudent, prior to physical screening for 
co-crystals, to conduct a computational pre-screen. This 
involves the use of computational chemistry such as utilising 
molecular quantum-mechanical calculations to predict drug-
co-former pairs that are likely to form co-crystals.
23
 Different 
methods are available from simple energy minimisation to full 
crystal structure prediction
24
 and the decision on which is most 
appropriate will be based on the size of the screen and the 
resources available. COSMOtherm software, which performs 
single molecule gas phase calculations based on polarisation 
charge densities, was chosen as the method of pre-screening 
for this work.
25
 Here ROY was screened against a list of 342 
potential co-formers following a similar screening process to 
that detailed by Grecu et. al.
26
 based on the previous work by 
Musumeci et. al.
23
 This modelling led to a list of energetically 
favourable combinations of co-former to ROY and those with 
the greatest enthalpic driver for interaction were taken 
forwards to the physical screen. The top ten from this list are 
shown in Table 1 ranked by excess enthalpy, obtained by 
subtracting the sum of calculated enthalpy of interaction of 
the pure components from that of the API-co-former mixture 
in the gas phase.  
 Physical high-throughput screening of potential co-formers 
with the desired API using ultrasonication has been proven to 
be feasible for this purpose with researchers employing 
variations such as SonicSlurry™ and sonic bath processes to 
introduce the sonic energy to the samples in 96-well 
plates.
27,28
 Having adopted ultrasonication technology for the 
screening process and adapted the current methods, key 
parameters for co-crystal screening were optimised to achieve 
a robust, cost effective process and this was applied to ROY. 
This was achieved by adding a DCM/ROY solution to an 
equimolar amount of solid potential co-former, which had 
been pre-weighed in a borosilicate glass 96-well plate. After 
leaving the initial solvent (DCM) to evaporate, acetone was 
added to 8 wells and the 8-tips of the ultrasonic probe were 
placed in these wells and sonicated. This process was repeated 
for the remaining wells and the whole process repeated a 
further two times replacing the solvent used each time; 
thereby completing the screening process in three solvents for 
48 potential co-formers. The products from each of the wells 
were analysed using FTIR (after each solvent) and compared to 
the spectra for the two parent compounds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Further details of the methods used can be found in the 
ESI†(S5). Full optimisation of this screening method is on-going 
and will be reported elsewhere.  
Here we report the discovery of a co-amorphous form of ROY, 
determined during follow up experimentation post co-crystal 
screening. Based on the analysis of the FTIR spectra, the screen 
applied to ROY found no evidence of the formation of co-
crystals. This was not surprising as a degree of excess enthalpy 
from prediction is no guarantee of co-crystallisation in-vitro, 
due to lack of consideration of the purported lattice in the 
adopted approach. The wavenumbers of the peaks of interest 
used in the analysis for the top 10 predicted co-formers are 
listed in Table 1, the results in their entirety can be found in 
the ESI†(S6). Further efforts to produce co-crystals of ROY 
from the top 10 predicted co-formers followed, this involved 
applying different methods of manufacture: liquid assisted 
grinding (LAG) and evaporative crystallisation. See ESI for 
details of these methods†.  
The products of LAG were analysed by FTIR, the results again 
listed in Table 1. In addition, the products of LAG were 
analysed by DSC employing a heat/cool/heat method (see ESI† 
for full details). Nine of the 10 products of LAG displayed 
unremarkable thermal recrystallization behaviour, however 
the LAG product of ROY and pyrogallol stood out. Pure ROY 
and pyrogallol show poor amorphous stability. Pyrogallol 
crystallises on cooling from melt and ROY crystallises during 
the second heating cycle (class (I-A) and class (II) materials 
following the classification system as described by Baird et. 
al.
29
 respectively), the product of the grind does not crystallise 
and remains in amorphous form throughout the temperature 
range tested. This suggests that an amorphous form was 
produced on cooling and this remained stable until at least 
150°C resulting in a material categorised as class (III); 
producing a co-amorphous material.
9
 The second heating 
cycles for the two parent components and the product of the 
1:1 molar ratio grind are shown in Figure 2. See ESI†(S12-13) 
for the initial heating and cooling cycles. This behaviour differs 
from all other ROY-co-former combinations, as they all  
 
 
 
 
 
 
 
 
 
Figure 1. Structures of ROY, Pyrogallol and PVP. 
Table 1 Top 10 predicted co-formers for ROY (aexcess enthalpy calculated for 1:1, 2:1 and 1:2 stoichiometric ratios of API to co-former and ranked by lowest. b Cycle in which 
crystallisation occurs during DSC of the grind of the respective co-former with ROY) 
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crystallise either on cooling (class (I)), on the second heating 
phase (class (II)), or in one case both, as shown in Table 1. 
The glass transition temperatures for ROY and for the ROY-
pyrogallol 1:1 grind, shown in Fig.2 and in more detail in the 
ESI†(S14), vary by less than 4°C, and as such suggest that a 
change in molecular mobility great enough to affect molecular 
translational ability is not caused by the presence of pyrogallol. 
To determine whether the amorphous stability elicited by the 
presence of the pyrogallol was related to its stoichiometric 
ratio with ROY, further ROY:pyrogallol samples were produced 
at 5% w/w increments from 0% to 100%, representative 
thermograms of the second heating cycle are shown in Fig.3 
and further results detailing the initial heating cycle can be 
found in the ESI†(S17,S18). The initial melting point varies very 
little over the range 5% to 95%w/w pyrogallol and therefore 
indicate that this is not a eutectic system, as, if it were, a single 
lower melting point at the eutectic composition would be 
expected.
30
 It is also worth noting that an endothermic melting 
peak at around 88.5°C was detected during the initial heating 
cycle is present in all three samples (S17), with decreasing 
intensity as the pyrogallol content is reduced.  
When looking at the second heating cycle (Fig. 3) at the 1:1 
composition the lack of any endothermic or exothermic events 
in the given temperature range suggest the 1:1 stabilisation  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rather than a small amount of pyrogallol inhibiting the 
crystallisation of ROY. The approximate boundaries of this 
range (25% to 35% w/w pyrogallol content) equate to molar 
ratios (in the form 1 ROY to X Pyrogallol) of 0.69 and 1.11 
respectively. These data suggest that with a lower ratio of 
pyrogallol to ROY, there is excess ROY behaving as pure ROY 
and uninfluenced by the presence of pyrogallol. The formation 
of intermolecular interactions between individual molecules of 
ROY and pyrogallol in a one to one manner would give rise to 
such behaviour.  
In order to explore this interaction the hydrogen bonding 
propensity of ROY, with the addition of aromatic hydroxyl to 
represent the potential pyrogallol interaction, was calculated 
using the logit model
31
 resulting in an area under ROC curve of 
0.86. (See ESI†(S19-22)) This predicted strong hydrogen bonds 
between molecules of ROY only. Further modelling utilising a 
200 molecule amorphous cell, generated in materials studio, 
displayed no change to the N-H bond of ROY, but changes to 
the environment around it (ESI† S23-S25). IR and solution 
1
H 
NMR were conducted on a physical sample. Solution 
1
H NMR 
showed a 1:1 product with no thermal degradation from the 
mixture (ESI† S26). Figure 4 displays the FTIR spectra of an 
amorphous sample of the ROY:Pyrogallol 1:1 grind and a peak 
shift corresponding to the N-H bond in ROY is apparent. A 
possible rationale, supported by the amorphous cell prediction 
(ESI† S23-S25), could be that of pyrogallol forms 
intermolecular bonds in proximity to the N-H bond of ROY 
causing the slight alteration in environment of the N-H bond. 
Such interactions in co-amorphous materials have previously 
been reported.
17
  
In order to compare the pyrogallol-stabilised amorphous ROY 
form to a more traditional polymer stabilised form, a grind of 
ROY with polyvinylpyrrolidone (PVP) was created. This was at 
both a typical 10%w/w drug loading, with regards to ROY, and 
also at a 1:1 molar ratio, based on the molecular weight of the 
PVP monomer. Both of these ROY:PVP ratios led to stabilised 
amorphous forms being produced. These data are available in 
the ESI†(S27-30). The similarity of the ROY:pyrogallol sample 
to the behaviour seen with the ROY:PVP grind adds further 
evidence to the possibility of replacing polymer with small 
molecule stabilising agents in some situations.  
 
 
 
 
 
 
 
 
Fig. 2 Second heating phase DSC curves of Pyrogallol (red), ROY (blue) and 
ROY:Pyrogallol 1:1 grind (green). Peak onset temperatures displayed. Presence 
of Tg highlighted in inset. 
Fig. 3 Second heating phase DSC curves of ROY (0%), Pyrogallol (100%) and varying 
compositions of ROY:Pyrogallol in 5% w/w increments. The red box highlights the range 
of compositions in which the amorphous form is stabilised.  This equates to 1:1 
stoichiometry.  
 
Fig. 4  - FTIR spectra of ROY (blue), ROY:Pyrogallol 1:1 grind (green) and amorphous 
ROY:Pyrogallol 1:1 grind (orange). Focused area of wavenumbers 3200-3400 shown in 
inset. 
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The timescale of the stability of the ROY:pyrogallol mix was 
also investigated by powder X-ray diffraction (PXRD) and DSC. 
This stability was seen to be highly dependent on atmospheric 
moisture conditions. Indeed samples stored under dry 
nitrogen flow, or in a lidded DSC pan were seen to be stable 
for up to 65 hours, with those exposed to atmospheric 
conditions only stable for around 30 minutes (ESI† S33-35). It 
was not possible to verify this through vapour sorption study 
due to the fast recrystallization that was seen on the 
instrument, but storage at 75% RH 25°C showed immediate 
visual recrystallization, which was confirmed by DSC at 18 
hours (ESI† S33). As compared to pure ROY this is a significant 
improvement however as complete recrystallization from the 
amorphous form was seen after 15 minutes.  
In this work the application of an optimised co-crystal screen, 
utilising computational tools to predict the most energetically 
favourable co-formers, has led to the discovery of no co-
crystals, but has highlighted a 1:1 interaction between ROY 
and pyrogallol. This interaction stabilises ROY in the 
amorphous form, although this stability is moisture 
dependent. Although predictive technology exists for single 
component amorphous phases,
32
 currently no predictive 
method for co-amorphous phases has been suggested and all 
screening is by trial and error. The discovery of this behaviour 
stemmed from a screen of 342 co-formers, in three 
stoichiometries, in which predicted interaction had been 
ranked highly in the gas phase. This suggests that co-crystal 
screening approaches can be modified to enable study into co-
amorphous phases and that ‘negative’ co-crystal hits should be 
investigated for alternative utility as co-amorphous materials. 
Such an approach would enable a broader palate of 
pharmaceutical development options and improve process 
efficiency.  
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